Cited by 211Thyroid Disorders and TreatmentsHeart Failure Treatment and ManagementThyroid and Parathyroid Surgery

Subclinical Thyroid Dysfunction and the Risk of Heart Failure in Older Persons at High Cardiovascular Risk

Open access
Nanchen, David, Gussekloo, Jacobijn, Westendorp, Rudi G. J., Stott, David J., Jukema, J. Wouter, Trompet, Stella, Ford, Ian, Welsh, Paul +6 more·2012·The Journal of Clinical Endocrinology & Metabolism

Abstract

CONTEXT: Subclinical thyroid dysfunction is common in older people. However, its clinical importance is uncertain. OBJECTIVE: Our objective was to determine the extent to which subclinical hyperthyroidism and hypothyroidism influence the risk of heart failure and cardiovascular diseases in older people. SETTING AND DESIGN: The Prospective Study of Pravastatin in the Elderly at Risk (PROSPER) is an prospective cohort study. PATIENTS: Patients included men and women aged 70-82 yr (n=5316) with known cardiovascular risk factors or previous cardiovascular disease. MAIN OUTCOME MEASURES: Incidence rate of heart failure hospitalization, atrial fibrillation, and cardiovascular events and mortality according to baseline thyroid status were evaluated. Euthyroid participants (TSH=0.45-4.5 mIU/liter) were compared with those with subclinical hyperthyroidism (TSH<0.45 mIU/liter) and those with subclinical hypothyroidism (TSH≥4.5 mIU/liter, both with normal free T4). RESULTS: Subclinical hyperthyroidism was present in 71 participants and subclinical hypothyroidism in 199 participants. Over 3.2 yr follow-up, the rate of heart failure was higher for subclinical hyperthyroidism compared with euthyroidism [age- and sex-adjusted hazard ratio (HR)=2.93, 95% confidence interval (CI)=1.37-6.24, P=0.005; multivariate-adjusted HR=3.27, 95% CI=1.52-7.02, P=0.002). Subclinical hypothyroidism (only at threshold>10 mIU/liter) was associated with heart failure (age- and sex-adjusted HR=3.01, 95% CI=1.12-8.11, P=0.029; multivariate HR=2.28, 95% CI=0.84-6.23). There were no strong evidence of an association between subclinical thyroid dysfunction and cardiovascular events or mortality, except in those with TSH below 0.1 or over 10 mIU/liter and not taking pravastatin. CONCLUSION: Older people at high cardiovascular risk with low or very high TSH along with normal free T4 appear at increased risk of incident heart failure.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.2011-1978

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Cardiovascular morbidity and mortality are particularly increased in men, in elderly patients with high-normal FT4 levels and in patients with underlying heart disease.

    “Cardiovascular morbidity and mortality are particularly increased in men, in elderly patients with high-normal FT 4 levels and in patients with underlying heart disease [71-73, 76, 77, 87, 91, 92, 94] .”

    From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [76]

    The Abstract (page unavailable) reports increased incident heart failure in older adults at high cardiovascular risk with low or very high TSH and normal FT4. The paper does not establish that cardiovascular morbidity and mortality are particularly increased in men, at high-normal FT4 levels, or specifically in patients with underlying heart disease; its Results report no significant overall association with cardiovascular events or mortality. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • The risk of heart failure was increased in the Prospective Study of Pravastatin in elderly patients with a history of cardiovascular disease.

    “The risk of HF was increased in the Prospective Study of Pravastatin (PROSPER Study) in elderly patients with a history of cardiovascular disease [76] .”

    From The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (2015) · cites this paper as [76]

    The Incident heart failure hospitalization section reports increased heart-failure hospitalization in PROSPER participants with subclinical hyperthyroidism compared with euthyroid participants, and says this association did not differ by history of CVD. The claim omits that thyroid-status comparison and describes the participants as having a history of cardiovascular disease, whereas the Study population section says they had either prior vascular disease or cardiovascular risk factors. (LLM, conf=0.86)

    Experimental — accuracy not yet measured
  • Some of these studies, including the meta-analyses, have also examined nonfatal cardiovascular events in SH, with similar increased risks.

    “Some of these studies, including the meta-analyses, have also examined nonfatal cardiovascular events in SH, with similar increased risks (383,388,390,391).”
  • Some other, smaller studies have reached similar conclusions, although other smaller studies have failed to find a correlation.

    “Some other, smaller studies have reached similar conclusions (374,383), although other smaller studies have failed to find a correlation (380,381,384,386).”
  • Some studies report increased overall mortality rates in SH subjects, especially older subjects, while others indicate no relation.

    “Some studies report increased overall mortality rates in SH subjects (374,379-383), especially older subjects, while others indicate no relation (384)(385)(386)(387).”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nanchen, D., Gussekloo, J., Westendorp, R. G. J., Stott, D. J., Jukema, J. W., Trompet, S., Ford, I., Welsh, P., Sattar, N., Macfarlane, P. W., Mooijaart, S. P., Rodondi, N., de Craen, A. J. M., & on behalf of the PROSPER Group
Affiliations
  • Leiden University Medical Center (NL)
  • Department of Public Health and Primary Care (J.G.), 2333 ZA Leiden, The Netherlands
  • University of Glasgow (GB)
  • Department of Cardiology (J.W.J.), 2333 ZA Leiden, The Netherlands
  • Robertson Centre for Biostatistics (I.F.), Glasgow G12 8QQ, United Kingdom
  • University of Bern (CH)
  • Leiden University Medical Center, Department of Gerontology and Geriatrics (D.N., R.G.J.W., S.T., S.P.M., A.J.M.d.C.), 2333 ZA Leiden, The Netherlands
Corresponding author
Nanchen, David
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-03-01
Volume
97
Issue
3
Pages
852-861
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2110776403
Cited by
211
References
34
Citations by year
2026: 5 · 2025: 5 · 2024: 11 · 2023: 13 · 2022: 15 · 2021: 14 · 2020: 9 · 2019: 15 · 2018: 12 · 2017: 22 · 2016: 11 · 2015: 25 · 2014: 13 · 2013: 25 · 2012: 14
FWCI
19.77
Type
journal article
Language
en
Open access
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Leiden Repository (Leiden University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
  • Bern Open Repository and Information System (University of Bern) (submittedVersion)
  • IRIS (submittedVersion)
  • SERVAL (Université de Lausanne) (submittedVersion)
Funders
  • National Science Foundation
  • Bristol-Myers Squibb
  • Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (132943, 138267, 320030)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek (050.060.810, 05040202)
  • Université de Lausanne
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
Keywords
subclinical hyperthyroidism, subclinical hypothyroidism, subclinical thyroid dysfunction, heart failure, heart failure hospitalization, older adults, cardiovascular risk, thyroid-stimulating hormone, atrial fibrillation, cardiovascular events, mortality, pravastatin, free thyroxine, TSH suppression therapy, statin therapy
MeSH terms
Aged, Aged, 80 and over, Atrial Fibrillation, Cardiovascular Diseases, Female, Follow-Up Studies, Heart Failure, Humans, Male, Prospective Studies, Risk, Risk Factors, Thyroid Diseases, Survival Rate

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review